Sierra Oncology, Inc. SRRA
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 54.98
- Prev close
- 54.99
- Mkt cap
- 1.34B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 54.98
- High
- 55.01
- Forward P/E
- -14.25
- Beta
- 0.02
- Short ratio
- 2.41
- Inst. own
- 76.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 4, 2022
- 50-d avg
- 54.73
- 200-d avg
- 33.69
- 1y target
- 55.00
Key statistics
- Market cap
- 1.34B
- Enterprise value
- 1.07B
- Trailing P/E
- 0.00
- Forward P/E
- -14.25
- PEG ratio
- -0.19
- Price / sales
- 0.00
- Price / book
- 5.00
- EPS (TTM)
- -6.59
- Beta
- 0.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -48.73M
- Total cash
- 274.02M
- Total debt
- 5.62M
- Return on equity
- -56.54%
- Shares outstanding
- 24.42M
- Short % of float
- 3.90%
- 50-day average
- 54.73
- 200-day average
- 33.69
Analyst view
Consensus: hold
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 4, 2022
Expected Aug 4, 2022. Consensus EPS estimate -0.95.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 4, 2022 | Jun 1, 2022 | -0.95 | — | — | — |
| May 6, 2022 | Mar 1, 2022 | -0.91 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -1.60 | — | — | — |
| Nov 5, 2021 | Sep 1, 2021 | -1.78 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -1.62 | — | — | — |
| May 7, 2021 | Mar 1, 2021 | -1.61 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 14, 2022 | Jefferies | down | Buy | Hold |
| Apr 14, 2022 | Oppenheimer | down | Outperform | Perform |
| Apr 13, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 14, 2022 | Oppenheimer | main | — | Outperform |
| Jan 31, 2022 | HC Wainwright & Co. | main | — | Buy |
| Nov 30, 2021 | Cantor Fitzgerald | main | — | Overweight |
About Sierra Oncology, Inc.
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sierraoncology.com
News
- GSK Receives Regulatory Nod for Consumer Healthcare Demerger
- SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
- SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
- Best Biotech Stocks To Buy Now? 5 To Know
- SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
- Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
- Why Is Sierra Oncology (SRRA) Stock Up Today?
- Sierra Oncology Stock Is Soaring: Here's Why
- Sierra Oncology Stock Soars After Buyout
- GSK to buy Sierra Oncology for $1.9 billion
Your note
Sign in to keep a note on SRRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABINGWORTH, L.L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 30, 2022 | 0 |
| AGGARWAL GAURAV | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 30, 2022 | 0 |
| ASHIYA MONA PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 25, 2022 | 0 |
| LONGITUDE CAPITAL PARTNERS III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 1, 2022 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 25, 2022 | 0 |
| RICHARDSON JOSHUA | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 1, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vivo Capital, LLC | 13.63% | 3,329,511 | 183.09M | Mar 30, 2022 |
| Frazier Life Sciences Management, L.P. | 9.59% | 2,342,198 | 128.80M | Mar 30, 2022 |
| Orbimed Advisors LLC. | 8.05% | 1,964,770 | 108.04M | Mar 30, 2022 |
| Abingworth, LLP | 5.38% | 1,314,012 | 72.26M | Mar 30, 2022 |
| Rock Springs Capital Management, LP | 4.81% | 1,174,786 | 64.60M | Mar 30, 2022 |
| PFM Health Sciences, LP | 4.35% | 1,062,888 | 58.45M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.44% | 351,614 | 19.34M | Mar 30, 2022 |
| BlackRock Health Sciences Trust II | 0.82% | 201,437 | 11.08M | Mar 30, 2022 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 0.77% | 187,929 | 10.33M | Feb 27, 2022 |
| Gabelli ABC Fund | 0.57% | 138,511 | 7.62M | Jun 29, 2022 |
| Fidelity Select Portfolios - Biotechnology | 0.21% | 52,000 | 2.86M | Mar 30, 2022 |
| Gabelli GDL Fund | 0.18% | 43,231 | 2.38M | Jun 29, 2022 |